Esophageal and gastric cancer highlights from ASCO GI 2024

In this podcast, we will discuss key insights from the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. Topics include updates in the KEYNOTE-811, MATTERHORN, and CheckMate 649 trials, as well as the use of circulating free DNA analysis in esophagogastric cancer and the evolving landscape of treatment of HER2-positve metastatic gastric cancer. Additionally, hear on a pilot PET study using the positron-emitting agent 18F-BMS-986229 for PD-L1 imaging in advanced esophagogastric cancer and a retrospective investigation into the concordance between three PD-L1 scoring methods and their association with clinical outcomes in RATIONALE-302.

Tune in to hear perspectives from experts such as Yelena Y. Janjigian (Memorial Sloan Kettering Cancer Center, New York, NY), Samuel Louis Cytryn (Memorial Sloan Kettering Cancer Center, New York, NY), Kohei Shitara (National Cancer Center Hospital East, Kashiwa, Japan), Ken Kato (National Cancer Center Hospital, Tokyo, Japan) and Nataliya V. Uboha (University of Wisconsin Carbone Cancer Center, Madison, WI).

The post Esophageal and gastric cancer highlights from ASCO GI 2024 appeared first on VJOncology.